Clinical trials: Nephropathy, Diabetic
Nephropathy, Diabetic
DEL-1 and Thromboxane A2 in Diabetic Nephropathy Patients
Diabetic nephropathy is one of the most common microvascular complications of diabetes mellitus and a leading cause of chronic kidney disease.
- Trial name
- DEL1-DN (NCT07749664)
- Testing
- No intervention
- Volunteers
- 80 people
- Sponsor
- Aswan University
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis
Study of WAL0921 in Patients With Glomerular Kidney Diseases
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and…
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
- Trial name
- NCT06466135
- Testing
- WAL0921
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 96 people
- Sponsor
- Walden Biosciences
Diabetic Kidney Disease, Hyperuricemia
Uric Acid Lowering Trial in Youth Onset T2D
Adolescents and young adults with youth-onset type 2 diabetes (T2D) are disproportionally impacted by hyperuricemia compared to non-diabetic peers and youth with type 1 diabetes (T1D).
- Conditions
- Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2
- Trial name
- ULTRA-T2D (NCT03899883)
- Testing
- Pegloticase 8 MG/ML [Krystexxa]
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Colorado, Denver
Diabetic Kidney Disease (DKD), Type 2 Diabetes
The Relationship Between Psychological Well-being, Social Support, and Disease Self-management in Patients With Diabetic Nephropathy
This study will look at the psychological well-being and social support of people with diabetic kidney disease and how these factors are related to how well they manage their condition.
- Trial name
- NCT07726589
- Where
- Taiwan
- Volunteers
- 161 people
- Sponsor
- National Taiwan University Hospital
Diabete Mellitus, Diabetic Nephropathy
Nephroprotective Effects of Fig (Ficus Carica L.) Leaf Supplementation
Diabetic nephropathy is the result of diabetes complications. Excessive blood glucose levels affect several organs which include liver, heart, and kidneys.The aim of this study is to use the nephroprotective and metabolic effects…
- Trial name
- NCT07718880
- Testing
- Control group, Intervention group
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- University of Lahore
Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Finerenone for the Treatment of Type 2 Diabetes-Related Kidney Disease: Efficacy Observation and Related Factor Analysis
This is a single-center prospective observational clinical study conducted at the First Affiliated Hospital of Chongqing Medical University.
- Trial name
- NCT07717697
- Testing
- Finerenone
- Volunteers
- 425 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Type 2 Diabetic Nephropathy With Elevated Blood Lead Burden
A Prospective Trial Of Oral Lead Chelation To Slow Renal Function Decline In Lead-Loaded Type 2 Diabetic Nephropathy Patients
This is a single-arm prospective clinical study conducted at The Fourth Affiliated Hospital of Zhejiang University School of Medicine.
- Trial name
- NCT07709871
- Testing
- Dimercaptosuccinic acid oral chelation therapy
- Volunteers
- 42 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Lead-Burdened Type 2 Diabetic Nephropathy
Intravenous Chelators in Lead-Burdened Type 2 Diabetic Nephropathy
Based on previous basic experiments revealing that patients with type 2 diabetic nephropathy exhibit higher blood lead levels than the general population, this study aims to systematically evaluate the impacts of short-term and…
- Trial name
- NCT07706946
- Testing
- chelator
- Volunteers
- 42 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Type 2 Diabetes Mellitus, Diabetic Kidney Disease
Evaluating the Effectiveness of a Smart Screening and Tiered Management Tool for Diabetic Kidney Disease in Primary Care: A Cluster Randomized Trial
This is a cluster-randomized controlled trial aiming to evaluate the effectiveness of an intelligent standardized screening and risk-stratified management tool for diabetic kidney disease (DKD) among adults with type 2 diabetes…
- Trial name
- SMART-DKD (NCT07707518)
- Testing
- Intervention Name Clinical decision support system for diabetic kidney disease (DKD-CDSS), Routine guideline-based diabetes management
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Diabetic Kidney Disease
Dosimetry of Tc-99m-Tilmanocept
This proposal will use kidney SPECT/CT of Tc-99m-tilmanocept to evaluate the mesangial changes seen in diabetics across the spectrum of kidney disease as well as persons with hypertensive kidney disease, the next most common…
- Trial name
- NCT05241522
- Testing
- Tc-99m-Tilmanocept
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Diabetic Kidney Disease (DKD)
Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease
This trial is to evaluate the efficacy and safety of umbilical cord-derived mesenchymal stromal cells (Amimestrocel ) in study subjects with progressive diabetic kidney disease (DKD), to investigate whether Amimestrocel can…
- Trial name
- MSC-DKD-001 (NCT06969807)
- Testing
- Amimestrocel
- Where
- 6 sites in China
- Volunteers
- 120 people
- Sponsor
- Chinese PLA General Hospital
Diabetic Nephropathy
Naoxintong Capsule for Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialAcronymNXT-DKD
Diabetic nephropathy (DN) is a leading cause of end-stage kidney disease worldwide and is associated with a high risk of cardiovascular events and mortality.
- Trial name
- NXT-DKD (NCT07698223)
- Testing
- Naoxintong Capsule
- Where
- 8 sites in China
- Volunteers
- 410 people
- Sponsor
- Chen Xiangmei
ANCA Associated Vasculitis, Extramembranous Glomerulopathy
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
The project is to explore in humans the hypothesis of the link between the alteration of tubulo-interstitial metabolism and the rate of deterioration of renal function by comparing various nephropathies.
- Conditions
- ANCA Associated Vasculitis, Extramembranous Glomerulopathy, Nephrotic Syndrome, Minimal Change, Interstitial Nephritis
- Trial name
- PROTECT-Fi (NCT07010250)
- Where
- France
- Volunteers
- 146 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Type 2 Diabetes, Proteinuria
Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)
The overall aim of the project is to elucidate the primary bio-psycho-social (BPS) risk factors for albuminuria in youth with type 2 diabetes (T2D) and the mechanisms by which they cause renal injury. The Study aims include: 1.
- Conditions
- Type 2 Diabetes, Proteinuria, Stress, Nephropathy
- Trial name
- iCARE (NCT02818192)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- University of Manitoba
Healthy Adult Participants, Diabetic Kidney Disease
Evaluation of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease
This is a phase 1 randomized, double-blind, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and Pharmacokinetics (PK) of single and multiple ascending doses of MTX-439…
- Trial name
- NCT07473323
- Testing
- MTX-439
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Mediar Therapeutics
Diabetic Kidney Disease, Type 2 Diabetes
Development and Validation of a Machine Learning Model for Differentiating Diabetic Kidney Disease and Non-Diabetic Kidney Disease in Type 2 Diabetes
This multicenter retrospective observational study aims to develop and validate an interpretable machine learning model for differentiating diabetic kidney disease (DKD) from non-diabetic kidney disease (NDKD) in patients with…
- Conditions
- Diabetic Kidney Disease, Type 2 Diabetes, Chronic Kidney Disease
- Trial name
- NCT07672639
- Where
- China
- Volunteers
- 2,201 people
- Sponsor
- Beijing Tongren Hospital
Diabetic Kidney Disease
Effect of Chinese Herbal Medicine on Renal Function in Diabetic Kidney Disease
This study is a randomized controlled pilot trial designed to evaluate the effects and safety of a traditional Chinese medicine formula (DKD-1) as an add-on therapy to standard treatment in patients with Diabetic Kidney Disease…
- Trial name
- NCT07657351
- Testing
- Chinese herbal formula DKD-1
- Where
- Taiwan
- Volunteers
- 66 people
- Sponsor
- China Medical University Hospital
Type 1 Diabetes, Diabetic Nephropathy
Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes
The purpose of this study is to determine whether alkalinization of urine uric acid by 2 doses of sodium bicarbonate (1950mg) over 24-hours reduces precipitation and crystallization of urine uric acid over in adults with type 1…
- Conditions
- Type 1 Diabetes, Diabetic Nephropathy, Diabetic Kidney Disease
- Trial name
- Alk-UA (NCT02502071)
- Testing
- sodium bicarbonate
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Colorado, Denver
Type 2 Diabetes, Diabetic Kidney Disease
Mechanism of SGLT2 Inhibition in the Kidney
The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in…
- Trial name
- NCT06291155
- Testing
- SGLT2 inhibitor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan
Chronic Kidney Disease
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in…
- Trial name
- NCT06150924
- Where
- 44 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mineralys Therapeutics Inc.